Current Event
Overview

• Targeting Key Antibacterial R&D Challenges
• Solving The Antibacterials Commercialization Equation

Short Course
Register 
PDF Download
Archives

Corporate Sponsors

 

  

2014 Attendee List 

Several factors, including diminishing financial return, and the lack of new discovery platforms and others, have had a cooling effect on pharmaceutical companies' activity in the area of antibacterial drug development. At the same time, we are witnessing the wide spread of resistant bacteria, leading to untreatable infections. "We are facing a huge crisis worldwide not having an antibiotics pipeline," said Dr. Janet Woodcock, the Director of CDER at FDA, in her recent interview for NYT. The governments of European countries and the United States have created several incentives for the industry to rise to the challenge, therefore, many companies are exploring the opportunities to start or re-open their antibacterial departments, or to stimulate the existing research and development. Cambridge Healthtech Institute is pleased to present its inaugural “Re-Entering Antibacterial Drug Development Summit” that includes a science track, a business track, and features a wide range of pivotal issues. This Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders, shaping the current state of antibacterial discovery and development.

CONFERENCE HIGHLIGHTS:

 

New discovery platforms, novel screens, and approaches are needed to develop new antibacterials, and to stop the dangerous trends of multidrug microbial resistance. The “Targeting the Key Antibacterial R&D Challenges” conference, part of the “Re-Entering Antibacterial Drug Development Summit”, is designed to serve as a scientific hub for researchers in the industry and academia working on new antibiotics. The following topics are going to be discussed: gram negatives, pathogen-specific drug development, antibacterial biologics, mechanisms of resistance, clinical microbiology, and others. Top industry and academia researcher are on the faculty of the meeting.   

FEATURED SPEAKER:

David C. Hooper, M.D., Professor of Medicine, Harvard Medical School; Chief, Infection Control Unit, Associate Chief, Division of Infectious Diseases, Massachusetts General Hospital

Barry Eisenstein, M.D., Senior Vice President, Scientific Affairs, Cubist Pharmaceuticals Editor, Antimicrobial Agents and Chemotherapy

TOPICS TO BE COVERED:

• Gram Negatives at The Top Of The Unmet Needs List
• Antibacterial Biologics
• The Bacterial Resistance Portfolio
• Sterilizing Antibiotics
• Technology To Serve Antibacterial R&D

 

The diminishing financial return, and high commercialization risks have led to the current state of antibacterial drug development. Many Pharma companies have left the field in the past decade due to those reasons. In the face of the growing unmet needs for new antibiotics, and wide spread of multidrug resistance bacteria governments, industry representatives are trying to get together to discuss the issues of clinical development and market access for new antibacterial agents. The “Solving The Antibacterials Commercialization Equation” conference, part of the “Re-Entering Antibacterial Drug Development Summit”, aims to encourage this dialogue. 

 

FEATURED SPEAKERS:

Timothy D. Hunt, Senior Vice President, Public Affairs, Cubist Pharmaceuticals

 Melissa Stundick, Ph.D., Branch Chief, BARDA’s Broad Spectrum Antimicrobial Program

TOPICS TO BE COVERED:

• Antibacterial Market Environment And Market Access Strategy
• Early Pricing Planning And Negotiations for A Product in Clinical Development
• Improving The Economics In The Antibiotic Market
• The Changing Landscape of Antibacterial Drug Development: The Role of Rapid Diagnostics
• Venture Capital Panel Discussion

October 28 Dinner Short Course:

Funding Opportunities for Antibacterial Research 

 

 

Targeting Key Antibacterial R&D Challenges | Solving The Antibacterials Commercialization Equation